Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01969123
Recruitment Status : Terminated (Study has been suspended due to clinical hold.)
First Posted : October 25, 2013
Last Update Posted : May 3, 2016
Information provided by (Responsible Party):
FORUM Pharmaceuticals Inc

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Dementia Drug: Drug: EVP-6124 Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 474 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Study Start Date : October 2013
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : January 2017

Arm Intervention/treatment
Experimental: Experimental: EVP-6124, low dose
low dose, Tablet, Once Daily, Day 1 through Day 182
Drug: Drug: EVP-6124
Experimental: Experimental: EVP-6124, high dose
high dose, Tablet, Once Daily, Day 1 through Day 182
Drug: Drug: EVP-6124
Placebo Comparator: EVP-6124 Placebo
Placebo, Tablet, Once Daily, Day 1 through Day 182
Drug: Placebo

Primary Outcome Measures :
  1. Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182 [ Time Frame: Baseline to Day 182 or Early Termination ]
  2. Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182 [ Time Frame: Baseline to Day 182 or Early Termination ]
  3. Safety and tolerability of EVP-6124 or Placebo in Subjects with AD [ Time Frame: Baseline to Day 182 or ET ]
    All adverse experiences spontaneously reported by subject and/or observed by an investigator and repeated clinical evaluation of physical exam, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG and laboratory tests (hematology/blood chemistry/urinalysis)

Secondary Outcome Measures :
  1. Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD) [ Time Frame: Baseline to Day 182 or Early Termination ]
  2. Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI) [ Time Frame: Baseline to Day 182 or Early Termination ]
  3. Change from Baseline in the Mini-Mental State Examination (MMSE) [ Time Frame: Baseline to Day 182 or Early Termination ]
  4. Change from Baseline in the Controlled Oral Word Association Test (COWAT) [ Time Frame: Baseline to Day 182 or Early Termination ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages ≥55 and ≤85 years
  • Informed consent form (ICF) signed by the subject or legally acceptable representative before any study-specific procedures for the subject are performed and an ICF signed by the support person/caregiver before any study-specific procedures for the support person/caregiver are performed
  • Clinical diagnosis of dementia due to probable AD consistent with criteria established by a workgroup of the National Institute on Aging and the Alzheimer's Disease Association
  • Clinical decline within 12 months before screening and onset of symptoms at least 12 months or longer before screening, which may include any documented cognition, functional, or other objective assessment or the clinical judgment of the investigator or the subject's referring physician that the subject has experienced a clinical decline within the last 12 months
  • Magnetic resonance imaging (MRI) or computed tomography (CT) scan performed within 12 months before screening, with findings consistent with the diagnosis of dementia due to AD without any other clinically significant comorbid pathologies. If an MRI or CT scan is unavailable or occurred greater than 12 months before screening, this assessment should be completed and the findings confirmed before the subject enters the run-in period (Day -14) (copy of the report will be available at the study site)
  • Mini-Mental State Examination (MMSE) score ≥14 and ≤24 at screening and confirmed on Day 1 prior to randomization (fluctuations of ±2 points are acceptable on Day 1/baseline)
  • Clinical Dementia Rating Global score (CDR-GS) ≥1 (at least mild dementia) at screening and confirmed on Day 1 prior to randomization
  • Modified Hachinski Ischemic Scale (mHIS) score ≤4 at screening
  • Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study. Female subjects and the female partner of male subjects must be surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least 1-year, or willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method])
  • Reliable and capable support person/caregiver, who if not living in the same household, interacts with the subject approximately 4 times per week and will be available to attend clinic visits in person when possible
  • Subject living at home, senior residential setting, or an institutional setting without the need for continuous (ie, 24-hour) nursing care
  • General health status acceptable for participation in a 26-week study
  • Fluency (oral and written) in the language in which the standardized tests will be administered
  • Receiving a stable dose of an acetylcholinesterase inhibitor (AChEI) (donepezil, rivastigmine or galantamine) for at least 3 months (90 days) before screening and with continuous dosing for at least 6 months OR not presently receiving an AChEI (at least 30 days before screening), but with a history of previous AChEI treatment (subjects receiving donepezil 23 mg currently or within 3 months before screening are ineligible)

Exclusion Criteria:

  • Exposure to an experimental drug, experimental biologic or experimental medical device within 2 months (60 days) before screening
  • Prior participation in an amyloid vaccination clinical study at any time in the past or completion of a passive amyloid vaccination study within 6 months before screening
  • Inability to swallow a tablet
  • In the judgment of the investigator, inability of the subject or the support person/caregiver to complete a 26-week study
  • Inability to be ≥75% compliant with single-blind study drug
  • Inability to adequately cooperate or complete the cognitive testing procedures or any study assessment
  • Residence in a skilled nursing facility
  • Untreated vitamin B12 or folate deficiency (if treated, must be stably treated for at least 6 months before screening)
  • Clinically significant (in the judgment of the investigator) abnormal serum electrolytes (sodium, potassium, magnesium) after repeat testing
  • Clinically significant untreated hypothyroidism (if treated, thyroid-stimulating hormone level and thyroid supplementation dose must be stable for at least 6 months before screening)
  • Insufficiently controlled diabetes mellitus (in the judgment of the investigator) or requiring insulin
  • Renal insufficiency (serum creatinine >2.0 mg/dL)
  • Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer)
  • Female subjects who are pregnant, nursing, or planning to become pregnant during the study
  • Unstable medical condition that is clinically significant in the judgment of the investigator
  • Alanine transaminase (ALT) or aspartate transaminase (AST) >2.5 times the upper limit of normal
  • History of myocardial infarction or unstable angina within 6 months before screening
  • History of more than 1 myocardial infarction within 5 years before screening
  • Clinically significant (in the judgment of the investigator) cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (subjects with a pacemaker are acceptable)
  • Symptomatic hypotension or hypertension (supine diastolic blood pressure >95 mmHg) (in the judgment of the investigator)
  • Clinically significant abnormality on screening or baseline electrocardiogram (ECG), including but not necessarily limited to a confirmed corrected QT interval (QTc) value ≥450 msec for males or ≥470 msec for females. In subjects with a QRS value >120msec, those with a QTc value <500 msec may be eligible following discussion with the Medical Monitor.
  • Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia
  • History of brain tumor, subdural hematoma, or other clinically significant (in the judgment of the investigator) space-occupying lesion on CT or MRI
  • Head trauma with clinically significant (in the judgment of the investigator) loss of consciousness within 12 months before screening or concurrent with the onset of dementia
  • Onset of dementia secondary (in the judgment of the investigator) to cardiac arrest, surgery with general anesthesia, or resuscitation
  • Specific degenerative central nervous system (CNS) disease diagnosis other than AD (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Fronto-Temporal Dementia, Parkinson's disease)
  • Subjects with no history of prior treatment with an AChEI (donepezil, rivastigmine, or galantamine)
  • Memantine currently or within 30 days before screening
  • Antipsychotics; low doses (in the judgment of the investigator, except clozapine) are allowed only if given for sleep disturbances, agitation and/or aggression, and only if the subject has received a stable dose for at least 3 months before screening (but not within 8 hours before any cognitive test)
  • Tricyclic antidepressants and monoamine oxidase inhibitors; all other antidepressants are allowed only if the subject has received a stable dose for at least 3 months before screening
  • Antiepileptic medications if taken for control of seizures
  • Chronic intake of opioid-containing analgesics
  • Sedating H1 antihistamines
  • Nicotine therapy (including the patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening
  • Clinically significant urine drug screen or serum alcohol test result in the judgment of the investigator
  • History of ischemic colitis or ischemic enterocolitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01969123

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, California
Costa Mesa, California, United States
Encino, California, United States
Glendale, California, United States
Long Beach, California, United States
Redding, California, United States
San Diego, California, United States
United States, Florida
Atlantis, Florida, United States
Brooksville, Florida, United States
Delray Beach, Florida, United States
Fort Myers, Florida, United States
Lake Worth, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
St. Petersburg, Florida, United States
Weston, Florida, United States
United States, Georgia
Columbus, Georgia, United States
Douglasville, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
Park Ridge, Illinois, United States
United States, Louisiana
Baton Rouge, Louisiana, United States
United States, Maine
Bangor, Maine, United States
United States, Massachusetts
Chestnut Hill, Massachusetts, United States
Plymouth, Massachusetts, United States
United States, Mississippi
Flowood, Mississippi, United States
United States, Missouri
Creve Coeur, Missouri, United States
United States, New Jersey
Princeton, New Jersey, United States
Springfield, New Jersey, United States
United States, New York
Brooklyn, New York, United States
Latham, New York, United States
New York, New York, United States
Staten Island, New York, United States
United States, North Carolina
Wilmington, North Carolina, United States
United States, Ohio
Columbus, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Norristown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Texas
San Antonio, Texas, United States
Wichita Falls, Texas, United States
United States, Utah
Murray, Utah, United States
Salt Lake City, Utah, United States
United States, Vermont
Bennington, Vermont, United States
United States, Virginia
Williamsburg, Virginia, United States
Australia, New South Wales
Hornsby, New South Wales, Australia
Australia, Victoria
Geelong, Victoria, Australia
West Heidelberg, Victoria, Australia
Brussels, Belgium
Leuven, Belgium
St. Truiden, Belgium
Canada, British Columbia
Kelowna, British Columbia, Canada
Canada, Ontario
Chatham, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Gatineau, Quebec, Canada
Nice, France
Paris, France
Rouen, France
Toulouse cedex 9, France
Achim, Germany
Köln, Germany
Munchen, Germany
Nurnberg, Germany
Brescia, Italy
Milano, Italy
Korea, Republic of
Seongnam-si, Gyenggi-go, Korea, Republic of
Busan, Korea, Republic of
Seoul, Korea, Republic of
Guadalajara, Jalisco, Mexico
Monterrey, Nuevo Leon, Mexico
Bialystok, Poland
Bydgoszcz, Poland
Poznan, Poland
Warszawa, Poland
South Africa
Bellville, South Africa
Johannesburg, South Africa
Pretoria, South Africa
Somerset West, South Africa
Elche, Altcante, Spain
Terrassa, Barcelona, Spain
Barcelona, Spain
Burgos, Spain
Madrid, Spain
Sponsors and Collaborators
FORUM Pharmaceuticals Inc

Responsible Party: FORUM Pharmaceuticals Inc Identifier: NCT01969123     History of Changes
Other Study ID Numbers: EVP-6124-024
2013-002618-10 ( EudraCT Number )
First Posted: October 25, 2013    Key Record Dates
Last Update Posted: May 3, 2016
Last Verified: September 2015

Keywords provided by FORUM Pharmaceuticals Inc:
Alzheimer's disease
Alpha-7 nAChR

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs